RxDoctor Payments Data

Joseph Mascolo, APRN

Nurse Practitioner · Vernon, CTNPI 1962062927

Payments from drug & device makers

$900in general payments, 2019–2025

Across 45 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • MDD US Operations, LLC$268
  • AbbVie$147
  • Noctrix Health, Inc.$82
  • Acadia Pharmaceuticals Inc$72
  • Supernus Pharmaceuticals, Inc.$70
  • Revance Therapeutics, Inc.$49
  • plus $212 from 8 others

What the payments were for

  • Food & beverage$900100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$900 in reported general payments places this provider in the 85th percentile of 1,162 nurse practitioner providers in Connecticut.

See all nurse practitioner providers in Connecticut

Medicare billing

Part B allowed, 2024
$92,395
Medicare patients
418
Services billed
744

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate187$1,064,835
IngrezzaValbenazine Tosylate61$546,116
AustedoDeutetrabenazine64$408,352
RytaryCarbidopa/Levodopa149$233,591
NourianzIstradefylline69$215,523
Austedo XrDeutetrabenazine36$204,986
GocovriAmantadine Hcl75$184,694
ApokynApomorphine Hcl11$184,136
XadagoSafinamide Mesylate35$110,557
NeuproRotigotine48$71,864
InbrijaLevodopa22$55,678
Carbidopa-LevodopaCarbidopa/Levodopa1,305$50,150
Rasagiline Mesylate236$35,014
OngentysOpicapone33$31,893
HorizantGabapentin Enacarbil22$24,354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$72$1,064,835187 claims
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$43$578,01094 claims
Amneal Pharmaceuticals LLCRytary$42$233,591149 claims
Kyowa Kirin, Inc.Nourianz$28$215,52369 claims
MDD US Operations, LLCGocovri$268$184,69475 claims
Acorda Therapeutics, IncInbrija$19$55,67822 claims
Avion PharmaceuticalsDhivy$14$12,68419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,162 nurse practitioner providers in Connecticut.

Other nurse practitioner in Vernon

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →